A Prospective Longitudinal Collection of Peripheral Blood to Support the Validation of Biomarkers as an Aid in Monitoring Disease in Patients with all Stages of Lung Cancer.
EvergreenHealth Pulmonary Care is conducting a study to evaluate blood specimens from women and men who have been diagnosed with lung cancer to support the validation of biomarkers as an aid in monitoring disease in patients with all stages of lung cancer.
Who may be eligible to participate?
Subjects 22 years of age and older with histologic/pathologic confirmation of lung cancer. Other inclusion/exclusion criteria apply.
What does participation involve?
Study visits will be conducted at times when a subject’s regular doctor routinely evaluates his/her lung cancer through radiographic imaging such as a CT scan, PET scan, PET/CT scan or X-ray.
Approximately two tablespoons of blood will be drawn from a vein in the subject’s arm at each visit, a minimum of three but no more than 12 times over the course of three years. The frequency of blood draws is determined by the stage of disease and the doctor’s standard of care treatment plan.
Investigator
Lindy Klaff, MD, EvergreenHealth Pulmonary Care
